The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.

This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited, often resulting in lifelong management rather than a cure. This technology offers a precise and efficient method to modify genes, potentially correcting the underlying causes of these disorders. By utilizing cutting-edge CRISPR technology, this solution not only enhances the accuracy of gene editing but also minimizes off-target effects, making it a safer option for therapeutic use. Stakeholders in the healthcare and biotechnology sectors should care about this technology as it represents a significant advancement in the pursuit of curative treatments for previously untreatable conditions. The licensing opportunity for this technology is open for collaboration with industry partners who are interested in further developing and commercializing these innovative therapeutic solutions. We are looking for partners who can contribute to the next stages of development and bring these therapies to market.